UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Baclofen decreases acid and non‐acid post‐prandial gastro‐oesophageal reflux measured by combined multichannel intraluminal impedance and pH

Alimentary pharmacology & therapeutics, 2003-01, Vol.17 (2), p.243-251

2003

Volltextzugriff (PDF)

Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects

Gastroenterology (New York, N.Y. 1943), 1998-12, Vol.115 (6), p.1335-1339

1998

Volltextzugriff (PDF)

Proton pump inhibitors: better acid suppression when taken before a meal than without a meal

Alimentary pharmacology & therapeutics, 2000-10, Vol.14 (10), p.1267-1272

2000

Volltextzugriff (PDF)

Editorial: refractory GERD—good drug, wrong patients?

Alimentary pharmacology & therapeutics, 2017-07, Vol.46 (2), p.203-204

Katz, P. O.

2017

Volltextzugriff (PDF)

Commentary: revisiting the past – does it hold the key to the future treatment of refractory GERD?

Alimentary pharmacology & therapeutics, 2013-07, Vol.38 (2), p.202-203

2013

Volltextzugriff (PDF)

Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis

Alimentary pharmacology & therapeutics, 2007-03, Vol.25 (5), p.617-628

2007

Volltextzugriff (PDF)

Gastro‐oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors

Alimentary pharmacology & therapeutics, 1998-12, Vol.12 (12), p.1231-1234

1998

Volltextzugriff (PDF)

Benchmarks for the interpretation of esophageal high‐resolution manometry

Neurogastroenterology and motility, 2017-04, Vol.29 (4), p.np-n/a

2017

Volltextzugriff (PDF)

Intragastric acid suppression and pharmacokinetics of twice‐daily esomeprazole: a randomized, three‐way crossover study

Alimentary pharmacology & therapeutics, 2004-08, Vol.20 (4), p.399-406

2004

Volltextzugriff (PDF)

Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors

Alimentary pharmacology & therapeutics, 2001-09, Vol.15 (9), p.1351-1356

2001

Volltextzugriff (PDF)

Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro‐oesophageal reflux disease – comparator study of esomeprazole, lansoprazole and pantoprazole

Alimentary pharmacology & therapeutics, 2010-07, Vol.32 (2), p.200-208

2010

Volltextzugriff (PDF)

Esophageal function testing using multichannel intraluminal impedance

American journal of physiology: Gastrointestinal and liver physiology, 2001-03, Vol.280 (3), p.G457-G462

2001

Volltextzugriff (PDF)

Prevalence, knowledge and care patterns for gastro‐oesophageal reflux disease in United States minority populations

Alimentary pharmacology & therapeutics, 2010-09, Vol.32 (5), p.645-654

2010

Volltextzugriff (PDF)

Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies

Alimentary pharmacology & therapeutics, 2011-01, Vol.33 (2), p.203-212

2011

Volltextzugriff (PDF)

Comparison of the effects of immediate‐release omeprazole oral suspension, delayed‐release lansoprazole capsules and delayed‐release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night‐time GERD symptoms

Alimentary pharmacology & therapeutics, 2007-01, Vol.25 (2), p.197-205

2007

Volltextzugriff (PDF)

Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily

Alimentary pharmacology & therapeutics, 1998-12, Vol.12 (12), p.1235-1240

1998

Volltextzugriff (PDF)

Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis

Alimentary pharmacology & therapeutics, 2003-11, Vol.18 (9), p.875-882

2003

Volltextzugriff (PDF)

Imipramine decreases oesophageal pain perception in human male volunteers

Gut, 1998-06, Vol.42 (6), p.807-813

1998

Volltextzugriff (PDF)

A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?

Alimentary pharmacology & therapeutics, 2010-08, Vol.32 (3), p.443-447

2010

Volltextzugriff (PDF)

Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms

The American journal of gastroenterology, 1999-06, Vol.94 (6), p.1464-1467

1999

Volltextzugriff (PDF)

Body mass index greater than 35 is associated with severe Clostridium difficile infection

Alimentary pharmacology & therapeutics, 2017-01, Vol.45 (1), p.75-81

2017

Volltextzugriff (PDF)

Review article: intragastric and oesophageal pH monitoring in patients with gastro‐oesophageal reflux disease

Alimentary pharmacology & therapeutics, 2006-03, Vol.23 (s1), p.3-11

KATZ, P. O.

2006

Volltextzugriff (PDF)

Gastric acidity and acid breakthrough with twice‐daily omeprazole or lansoprazole

Alimentary pharmacology & therapeutics, 2000-06, Vol.14 (6), p.709-714

2000

Volltextzugriff (PDF)

Maximal acid reflux control for Barrett’s oesophagus: feasible and effective

Alimentary pharmacology & therapeutics, 2001-04, Vol.15 (4), p.519-524

2001

Volltextzugriff (PDF)

Editorial: do we have a new addition to our GERD treatment tool box?

Alimentary pharmacology & therapeutics, 2016-02, Vol.43 (4), p.541-542

2016

Volltextzugriff (PDF)

1 – 25 von 963

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(829)
Mit Volltextzugriff
(732)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Baclofen decreases acid and non‐acid post‐prandial gastro‐oesophageal reflux measured by combined multichannel intraluminal impedance and pH

Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects

Proton pump inhibitors: better acid suppression when taken before a meal than without a meal

Editorial: refractory GERD—good drug, wrong patients?

Commentary: revisiting the past – does it hold the key to the future treatment of refractory GERD?

Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis

Gastro‐oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors

Benchmarks for the interpretation of esophageal high‐resolution manometry

Intragastric acid suppression and pharmacokinetics of twice‐daily esomeprazole: a randomized, three‐way crossover study

Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors

Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro‐oesophageal reflux disease – comparator study of esomeprazole, lansoprazole and pantoprazole

Esophageal function testing using multichannel intraluminal impedance

Prevalence, knowledge and care patterns for gastro‐oesophageal reflux disease in United States minority populations

Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies

Comparison of the effects of immediate‐release omeprazole oral suspension, delayed‐release lansoprazole capsules and delayed‐release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night‐time GERD symptoms

Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily

Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis

Imipramine decreases oesophageal pain perception in human male volunteers

A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?

Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms

Body mass index greater than 35 is associated with severe Clostridium difficile infection

Review article: intragastric and oesophageal pH monitoring in patients with gastro‐oesophageal reflux disease

Gastric acidity and acid breakthrough with twice‐daily omeprazole or lansoprazole

Maximal acid reflux control for Barrett’s oesophagus: feasible and effective

Editorial: do we have a new addition to our GERD treatment tool box?

Suchergebnisse filtern